Top Markets
#1 Trillions Trillions +5,127.61%
#2 Black Phoenix Black Phoenix +4,074.95%
#3 DeFiChain DeFiChain +1,700.88%
#4 Siren Siren +198.16%
#5 Bedrock Bedrock +120.41%
#6 KONET KONET +64.17%
#7 inSure DeFi inSure DeFi +60.27%
#8 Aria.AI Aria.AI +59.06%
#9 Banana For Scale Banana For Scale +46.83%
#10 TRIA TRIA +26.51%
Coin of the day
Trillions Trillions
Settings
Language
ENGLISH
Currency
USD
Theme
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVB
Rank in Stocks #99999
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the... Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.
Share Price
$0.09933121
Market Cap
$29.15K
Change (1 day)
0.57%
Change (1 year)
449.49%
Country
IE
Trade Ovoca Bio plc (OVB)

Category

Healthcare
Revenue for Ovoca Bio plc (OVB)
Revenue in Jun 2024 TTM: 0.00
According to Ovoca Bio plc latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of 0.00 equal to the revenue in the year 2022 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ovoca Bio plc from 2001 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 0.00%
2001 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -
NL